References
- Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004;5:1–6
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–61
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–90
- Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms. Cancer 2009;115:3842–7
- Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162–8
- Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281–3
- Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8–14
- Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–83
- Lim J, Taoka B, Otte RD, et al. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. J Med Chem 2011;54:7334–49
- Ligprep, Version 2.6, Schrödinger, LLC, NY, 2013
- Qikprop, Version 3.6, Schrödinger, LLC, NY, 2013
- Cavalli A, Poluzzi E, De Ponti F, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 2002;45:3844–53
- Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 1998;15:1490–4
- Luco JM. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J Chem Inf Comput Sci 1999;39:396–404
- Irvine JD, Takahashi L, Lockhart K, et al. MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999;88:28–33
- Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9:663–9
- Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 2001;44:4370–8
- Kelder J, Grootenhuis PD, Bayada DM, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999;16:1514–19
- Protein Preparation Wizard, Prime Version 3.5, Schrödinger, LLC, NY, 2013
- Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
- Friesner RA, Murphy RB, Repasky MP, et al. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem 2006;49:6177–96
- Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9
- Glide Version 5.9, Schrödinger, LLC, NY, 2013
- Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a novel approach to pharmacophore modeling and 3D database searching. J Comput Aided Mol Des 2006;20:647–71
- Phase, Version 3.5, Schrödinger, LLC, NY, 2013
- Basu A, Jasu K, Jayaprakash V, et al. Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives. Eur J Med Chem 2009;44:2400–7
- Golbraikh A, Tropsha A. Beware of q2!. J Mol Graph Model 2002;20:269–76
- Lu P, Wei X, Zhang R. CoMFA and CoMSIA 3D-QSAR studies on quionolone carboxylic acid derivatives inhibitors of HIV-1 integrase. Eur J Med Chem 2010;45:3413–19